EICHORPublic-registry site landscape for NCT05099172, “First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)”, a Advanced Non-small Cell Lung Cancer study sponsored by Bayer. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05099172 (registry record) |
| Study title | First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) |
| Official title | An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation |
| Sponsor | Bayer |
| Condition(s) | Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 94 |
| Site countries | United States, Belgium, Brazil, China, France, Hong Kong, Israel, Italy, Japan, Netherlands, Poland, Portugal |
Patient-friendly overview of this study: eichor.com/study/NCT05099172.
Eichor generates a preliminary site-risk snapshot for NCT05099172 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
← Eichor home · All tracked trials · Advanced Non-small Cell Lung Cancer studies · Weekly briefs
